SOUTH SAN FRANCISCO, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Vicinitas Therapeutics, a biotechnology company advancing a proprietary targeted protein stabilization platform to develop novel therapeutics for cancer and genetic disorders, today announced the appointment of Adam Hughes, Ph.D., as Chief Scientific Officer.

加利福尼亚州南旧金山，2024年5月2日（环球通讯社）--Vicinitas Therapeutics是一家生物技术公司，致力于开发专有的靶向蛋白质稳定平台，以开发针对癌症和遗传疾病的新型疗法，今天宣布任命Adam Hughes博士为首席科学官。

Dr. Hughes previously served as VP of Medicinal Chemistry at Vicinitas. “We continue to make notable progress advancing our proprietary Deubiquitinase Targeting Chimera, or DUBTAC, platform, which is designed to restore aberrantly degraded proteins and deliver new therapeutic options to patients with cancer and genetic disorders,” said Christian Hofmann, Ph.D., Chief Executive Officer of Vicinitas Therapeutics.

休斯博士曾担任维吉尼塔斯药物化学副总裁。Vicinitas Therapeutics首席执行官克里斯蒂安·霍夫曼（Christian Hofmann）博士说：“我们继续在推进我们专有的去泛素化酶靶向嵌合体（DUBTAC）平台方面取得显着进展，该平台旨在恢复异常降解的蛋白质，并为癌症和遗传疾病患者提供新的治疗选择。”。

“Adam has been an integral part of building the platform since the founding of the company, and I’m thrilled to now have him at the helm of our scientific organization as Chief Scientific Officer. His extensive experience discovering heterobifunctional molecules and advancing platform-derived clinical candidates, coupled with his demonstrated leadership skills, will be critical as we continue to build a discovery pipeline of differentiated therapeutics.” Dr.

“自公司成立以来，亚当一直是构建平台不可或缺的一部分，现在我很高兴他担任我们科学组织的首席科学官。他在发现异双功能分子和推进平台衍生临床候选人方面的丰富经验，加上他展示的领导技能，将对我们继续构建差异化治疗的发现渠道至关重要。”。

Hughes commented, “The onset and progression of many diseases, including cancer and monogenic diseases, are often caused by specific proteins that are abnormally degraded, thus preventing normal protein function. To date, many of these aberrantly degraded proteins have been intractable to drug discovery efforts.

休斯评论道：“包括癌症和单基因疾病在内的许多疾病的发生和发展通常是由异常降解的特定蛋白质引起的，从而阻止了正常的蛋白质功能。迄今为止，许多异常降解的蛋白质对药物发现工作来说是棘手的。

By leveraging our DUBTAC platform, we have a unique opportunity to develop small molecule drugs that can stabilize these proteins to prevent degradation and restore normal protein function. I’m very excited to continue contributing to Vicinitas’ mission, now as CSO, as we work to dru.

通过利用我们的DUBTAC平台，我们有一个独特的机会来开发可以稳定这些蛋白质以防止降解和恢复正常蛋白质功能的小分子药物。我很高兴能继续为Vicinitas的使命做出贡献，现在作为CSO，我们正在为dru工作。